A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

Xie,Lixin; Xie,Daihan; Du,Zhefei; Xue,Shaobo; Wang,Kesheng; Yu,Xin; Liu,Xiuli; Peng,Qiuxia; Fang,Chao

doi:10.3892/ijo.2024.5626

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

Authors:
- Lixin Xie
- Daihan Xie
- Zhefei Du
- Shaobo Xue
- Kesheng Wang
- Xin Yu
- Xiuli Liu
- Qiuxia Peng
- Chao Fang
View Affiliations

Affiliations: Department of Medical Ultrasound and Central Laboratory of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Tongji University, Shanghai 200072, P.R. China, Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, P.R. China
Published online on: February 21, 2024 https://doi.org/10.3892/ijo.2024.5626
Article Number: 38
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer represents a marked global public health concern. Despite existing treatment modalities, the average 5‑year survival rate for patients with patients with lung cancer is only ~20%. As there are numerous adverse effects of systemic administration routes, there is an urgent need to develop a novel therapeutic strategy tailored specifically for patients with lung cancer. Non‑invasive aerosol inhalation, as a route of drug administration, holds unique advantages in the context of respiratory diseases. Nanoscale materials have extensive applications in the field of biomedical research in recent years. The present study provides a comprehensive review of the classification, applications summarized according to existing clinical treatment modalities for lung cancer and challenges associated with inhalable micron/nanoparticle drug delivery systems (DDSs) in lung cancer. Achieving localized treatment of lung cancer preclinical models through inhalation is deemed feasible. However, further research is required to substantiate the efficacy and long‑term safety of inhalable micron/nanoparticle DDSs in the clinical management of lung cancer.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
2	Reck M, Remon J and Hellmann MD: First-Line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 40:586–597. 2022.
3	Hsu WH, Yang JC, Mok TS and Loong HH: Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 29(suppl_1): i3–i9. 2018.
4	Wei J, Luo X, Chen M, Lu J and Li X: Spatial distribution and antitumor activities after intratumoral injection of fragmented fibers with loaded hydroxycamptothecin. Acta Biomater. 23:189–200. 2015.
5	Dhanani J, Fraser JF, Chan HK, Rello J, Cohen J and Roberts JA: Fundamentals of aerosol therapy in critical care. Crit Care. 20:2692016.
6	Zhou QT, Tang P, Leung SS, Chan JG and Chan HK: Emerging inhalation aerosol devices and strategies: where are we headed? Adv Drug Deliv Rev. 75:3–17. 2014.
7	Matuszak M, Ochowiak M, Włodarczak S, Krupińska A and Doligalski M: State-of-the-art review of the application and development of various methods of aerosol therapy. Int J Pharm. 614:1214322022.
8	Ghosh S, Javia A, Shetty S, Bardoliwala D, Maiti K, Banerjee S, Khopade A, Misra A, Sawant K and Bhowmick S: Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. J Control Release. 337:27–58. 2021.
9	Ezhilarasan D, Lakshmi T and Mallineni SK: Nano-based targeted drug delivery for lung cancer: Therapeutic avenues and challenges. Nanomedicine (Lond). 17:1855–1869. 2022.
10	Liu Y, Xia Y, Smollar J, Mao W and Wan Y: The roles of small extracellular vesicles in lung cancer: Molecular pathology, mechanisms, diagnostics, and therapeutics. Biochim Biophys Acta Rev Cancer. 1876:1885392021.
11	Wu J, Wang X, Wang Q, Lou Z, Li S, Zhu Y, Qin L and Wei H: Nanomaterials with enzyme-like characteristics (nanozymes): Next-generation artificial enzymes (II). Chem Soc Rev. 48:1004–1076. 2019.
12	Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, Kabary DM, Freag MS, Samaha MW, Mortada SM, et al: Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 269:374–392. 2018.
13	Lee WH, Loo CY, Traini D and Young PM: Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. Expert Opin Drug Deliv. 12:1009–1026. 2015.
14	Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, Karamanos N and Zarogoulidis K: Inhaled chemotherapy in lung cancer: Future concept of nanomedicine. Int J Nanomedicine. 7:1551–1572. 2012.
15	Kuzmov A and Minko T: Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 219:500–518. 2015.
16	Mangal S, Gao W, Li T and Zhou QT: Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: Challenges and opportunities. Acta Pharmacol Sin. 38:782–797. 2017.
17	Gupta C, Jaipuria A and Gupta N: Inhalable formulations to treat non-small cell lung cancer (NSCLC): Recent therapies and developments. Pharmaceutics. 15:1392022.
18	Karathanasis E, Ayyagari AL, Bhavane R, Bellamkonda RV and Annapragada AV: Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release. 103:159–175. 2005.
19	Loira-Pastoriza C, Todoroff J and Vanbever R: Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev. 75:81–91. 2014.
20	Lee WH, Loo CY, Traini D and Young PM: Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. Asian J Pharm Sci. 10:481–489. 2015.
21	Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV and Tsuda A: Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol. 28:1300–1303. 2010.
22	Davis ME, Chen ZG and Shin DM: Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov. 7:771–782. 2008.
23	Kumar M, Jha A, Bharti K, Parmar G and Mishra B: Advances in lipid-based pulmonary nanomedicine for the management of inflammatory lung disorders. Nanomedicine (Lond). 17:913–934. 2022.
24	Lee WH, Loo CY, Young PM, Traini D, Mason RS and Rohanizadeh R: Recent advances in curcumin nanoformulation for cancer therapy. Expert Opin Drug Deliv. 11:1183–1201. 2014.
25	Rosière R, Amighi K and Wauthoz N: Chapter 10-Nanomedicine-Based Inhalation Treatments for Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Kesharwani P: Academic Press; pp. 249–268. 2019
26	Sorino C, Negri S, Spanevello A, Visca D and Scichilone N: Inhalation therapy devices for the treatment of obstructive lung diseases: The history of inhalers towards the ideal inhaler. Eur J Intern Med. 75:15–18. 2020.
27	French DL, Edwards DA and Niven RW: The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 27:769–783. 1996.
28	Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R and Edwards DA: Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 16:1735–1742. 1999.
29	Kuehl PJ, Grimes MJ, Dubose D, Burke M, Revelli DA, Gigliotti AP, Belinsky SA and Tessema M: Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Deliv. 25:1127–1136. 2018.
30	Chraibi S, Rosière R, De Prez E, Gérard P, Antoine MH, Langer I, Nortier J, Remmelink M, Amighi K and Wauthoz N: Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer. Biomed Pharmacother. 139:1117162021.
31	Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol. 23:1147–1157. 2005.
32	Coleman N, Yap TA, Heymach JV, Meric-Bernstam F and Le X: Antibody-drug conjugates in lung cancer: Dawn of a new era? NPJ Precis Oncol. 7:52023.
33	Shepard KB, Vodak DT, Kuehl PJ, Revelli D, Zhou Y, Pluntze AM, Adam MS, Oddo JC, Switala L, Cape JL, et al: Local treatment of non-small cell lung cancer with a spray-dried bevacizumab formulation. AAPS PharmSciTech. 22:2302021.
34	Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, et al: Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res. 25:1318–1326. 2008.
35	Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, et al: Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release. 196:344–354. 2014.
36	Brunaugh AD, Ding L, Wu T, Schneider M, Khalaf R and Smyth HDC: Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder. J Pharm Sci. 111:403–416. 2022.
37	Cortez-Jugo C, Qi A, Rajapaksa A, Friend JR and Yeo LY: Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics. 9:0526032015.
38	Wang X, Chen H, Zeng X, Guo W, Jin Y, Wang S, Tian R, Han Y, Guo L, Han J, et al: Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system. Acta Pharm Sin B. 9:167–176. 2019.
39	Ying N, Liu S, Zhang M, Cheng J, Luo L, Jiang J, Shi G, Wu S, Ji J, Su H, et al: Nano delivery system for paclitaxel: Recent advances in cancer theranostics. Colloids Surf B Biointerfaces. 228:1134192023.
40	Kumar R: Lipid-Based Nanoparticles for Drug-Delivery Systems-ScienceDirect. Nanocarriers for Drug Delivery. 249–284. 2019.
41	Gandhi S and Roy I: Lipid-Based inhalable micro- and nanocarriers of active agents for treating non-small-cell lung cancer. Pharmaceutics. 15:14572023.
42	Sedighi M, Sieber S, Rahimi F, Shahbazi MA, Rezayan AH, Huwyler J and Witzigmann D: Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach. Drug Deliv Transl Res. 9:404–413. 2019.
43	Minko T, Khandare JJ, Vetcher AA, Soldatenkov VA and Pozharov VP: Multifunctional Nanotherapeutics for Cancer. Fundamental Biomedical Technologies. 2008.
44	Szabová J, Mišík O, Fučík J, Mrázová K, Mravcová L, Elcner J, Lízal F, Krzyžánek V and Mravec F: Liposomal form of erlotinib for local inhalation administration and efficiency of its transport to the lungs. Int J Pharm. 634:1226952023.
45	Sarvepalli S, Parvathaneni V, Chauhan G, Shukla SK and Gupta V: Inhaled indomethacin-loaded liposomes as potential therapeutics against non-small cell lung cancer (NSCLC). Pharm Res. 39:2801–2815. 2022.
46	Fu F, Wang W, Wu L, Wang W, Huang Z, Huang Y, Wu C and Pan X: Inhalable biomineralized liposomes for cyclic Ca²⁺-burst-centered endoplasmic reticulum stress enhanced lung cancer ferroptosis therapy. ACS Nano. 17:5486–5502. 2023.
47	Zhang M, Li M, Du L, Zeng J, Yao T and Jin Y: Paclitaxel-in-liposome-in-bacteria for inhalation treatment of primary lung cancer. Int J Pharm. 578:1191772020.
48	Kulkarni JA, Witzigmann D, Leung J, Tam YYC and Cullis PR: On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 11:21733–21739. 2019.
49	Ganesan P and Narayanasamy D: Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 6:37–56. 2017.
50	Filipczak N, Yalamarty SSK, Li X, Khan MM, Parveen F and Torchilin V: Lipid-Based drug delivery systems in regenerative medicine. Materials (Basel). 14:53712021.
51	Mehnert W and Mäder K: Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 47:165–196. 2001.
52	Zimmermann CM, Baldassi D, Chan K, Adams NBP, Neumann A, Porras-Gonzalez DL, Wei X, Kneidinger N, Stoleriu MG, Burgstaller G, et al: Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release. 351:137–150. 2022.
53	Robins MM, Watson AD and Wilde PJ: Emulsions-creaming and rheology. Current Opinion in Colloid and Interface Science. 2002.
54	Ngan CL and Asmawi AA: Lipid-based pulmonary delivery system: A review and future considerations of formulation strategies and limitations. Drug Deliv Transl Res. 8:1527–1544. 2018.
55	Lovelyn C and Attama AA: Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol. 2:626–639. 2011.
56	Pandey P, Gulati N, Makhija M, Purohit D and Dureja H: Nanoemulsion: A novel drug delivery approach for enhancement of bioavailability. Recent Pat Nanotechnol. 14:276–293. 2020.
57	Jyoti K, Kaur K, Pandey RS, Jain UK, Chandra R and Madan J: Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J Colloid Interface Sci. 445:219–230. 2015.
58	Arbain NH, Salim N, Masoumi HRF, Wong TW, Basri M and Abdul Rahman MB: In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery. Drug Deliv Transl Res. 9:497–507. 2019.
59	Asmawi AA, Salim N, Abdulmalek E and Abdul Rahman MB: Modeling the effect of composition on formation of aerosolized nanoemulsion system encapsulating docetaxel and curcumin using D-Optimal mixture experimental design. Int J Mol Sci. 21:43572020.
60	Asmawi AA, Salim N, Abdulmalek E and Abdul Rahman MB: Size-Controlled preparation of docetaxel- and curcumin-loaded nanoemulsions for potential pulmonar y deliver y. Pharmaceutics. 15:6522023.
61	Xu M, Zhang L, Guo Y, Bai L, Luo Y, Wang B, Kuang M, Liu X, Sun M, Wang C and Xie J: Nanoemulsion Co-Loaded with XIAP siRNA and gambogic acid for inhalation therapy of lung cancer. Int J Mol Sci. 23:142942022.
62	Chauhan G, Wang X, Yousry C and Gupta V: Scalable production and in vitro efficacy of inhaled erlotinib nanoemulsion for enhanced efficacy in non-small cell lung cancer (NSCLC). Pharmaceutics. 15:9962023.
63	Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S and Yenugonda VM: Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives. Int J Nanomedicine. 14:1937–1952. 2019.
64	Zhang L, Chan JM, Gu FX, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R and Farokhzad OC: Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano. 2:1696–1702. 2008.
65	Bardoliwala D, Patel V, Misra A and Sawant K: Systematic development and characterization of inhalable dry powder containing Polymeric Lipid Hybrid Nanocarriers co-loaded with ABCB1 shRNA and docetaxel using QbD approach.
66	Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, et al: Polymeric Nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 25:37312020.
67	Mahar R, Chakraborty A, Nainwal N, Bahuguna R, Sajwan M and Jakhmola V: Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech. 24:392023.
68	Elbatanony RS, Parvathaneni V, Kulkarni NS, Shukla SK, Chauhan G, Kunda NK and Gupta V: Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)-development and in-vitro efficacy. Drug Deliv Transl Res. 11:927–943. 2021.
69	Gaikwad D, Shewale R, Patil V, Mali D, Gaikwad U and Jadhav N: Enhancement in in vitro anti-angiogenesis activity and cytotoxicity in lung cancer cell by pectin-PVP based curcumin particulates. Int J Biol Macromol. 104(Pt A): 656–664. 2017.
70	Rasul RM, Tamilarasi Muniandy M, Zakaria Z, Shah K, Chee CF, Dabbagh A, Rahman NA and Wong TW: A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. Carbohydr Polym. 250:1168002020.
71	Jin Q, Zhu W, Zhu J, Zhu J, Shen J, Liu Z, Yang Y and Chen Q: Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis. Adv Mater. 33:e20075572021.
72	Zhang M and Zhao X: Alginate hydrogel dressings for advanced wound management. Int J Biol Macromol. 162:1414–1428. 2020.
73	Karim A, Rehman A, Feng J, Noreen A, Assadpour E, Kharazmi MS, Lianfu Z and Jafari SM: Alginate-based nanocarriers for the delivery and controlled-release of bioactive compounds. Adv Colloid Interface Sci. 307:1027442022.
74	Alsmadi MM, Obaidat RM, Alnaief M, Albiss BA and Hailat N: Development, In Vitro Characterization, and In Vivo Toxicity Evaluation of Chitosan-Alginate Nanoporous Carriers Loaded with Cisplatin for Lung Cancer Treatment. AAPS PharmSciTech. 21:1912020.
75	Jiang X, Du Z, Zhang X, Zaman F, Song Z, Guan Y, Yu T and Huang Y: Gelatin-based anticancer drug delivery nanosystems: A mini review. Front Bioeng Biotechnol. 11:11587492023.
76	Gou S, Wang G, Zou Y, Geng W, He T, Qin Z, Che L, Feng Q and Cai K: Non-Pore Dependent and MMP-9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer. Adv Mater. 35:e23037182023.
77	Chowdhury S, Toth I and Stephenson RJ: Dendrimers in vaccine delivery: Recent progress and advances. Biomaterials. 280:1213032022.
78	Sapra R, Verma RP, Maurya GP, Dhawan S, Babu J and Haridas V: Designer Peptide and Protein Dendrimers: A Cross-Sectional Analysis. Chem Rev. 119:11391–11441. 2019.
79	Kalomiraki M, Thermos K and Chaniotakis NA: Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine. 11:1–12. 2015.
80	Conti DS, Brewer D, Grashik J, Avasarala S and da Rocha SR: Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm. 11:1808–1822. 2014.
81	B FCA, D FZ, E DSD, et al: Bioreducible and traceable Ru(III) prodrug-loaded mesoporous silica nanoparticles for sequentially targeted nonsmall cell lung cancer chemotherapy-ScienceDirect. Applied Materials Today.
82	Ma Z, Wang H, Shi Z, Yan F, Li Q, Chen J, Cui ZK, Zhang Y, Jin X, Jia YG and Wang L: Inhalable GSH-Triggered Nanoparticles to Treat Commensal Bacterial Infection in In Situ Lung Tumors. ACS Nano. 17:5740–5756. 2023.
83	Salama JK and Vokes EE: New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol. 31:1029–1038. 2013.
84	De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM and Hegi-Johnson F: Radiotherapy toxicity. Nat Rev Dis Primers. 5:132019.
85	Patel V, Papineni RV, Gupta S, Stoyanova R and Ahmed MM: A realistic utilization of nanotechnology in molecular imaging and targeted radiotherapy of solid tumors. Radiat Res. 177:483–495. 2012.
86	Wang H, Mu X, He H and Zhang XD: Cancer Radiosensitizers. Trends Pharmacol Sci. 39:24–48. 2018.
87	Hao Y, Altundal Y, Moreau M, Sajo E, Kumar R and Ngwa W: Potential for enhancing external beam radiotherapy for lung cancer using high-Z nanoparticles administered via inhalation. Phys Med Biol. 60:7035–7043. 2015.
88	Hou YJ, Yang XX, Liu RQ, Zhao D, Guo CX, Zhu AC, Wen MN, Liu Z, Qu GF and Meng HX: Pathological Mechanism of Photodynamic Therapy and Photothermal Therapy Based on Nanoparticles. Int J Nanomedicine. 15:6827–6838. 2020.
89	Xue S, Jiao J, Miao S, Wang L, Liu Y, Zhang Q, Wang Q, Xi Y and Zhang Y: Lipid-coated bismuth nanoflower as the thermos-radio sensiti for therapy of lung metastatic breast cancer: Preparation, optimisation, and characterisation. IET Nanobiotechnol. 16:305–315. 2022.
90	Wang Q, Liu J, Chen D, Miao S, Wen J, Liu C, Xue S, Liu Y, Zhang Q and Shen Y: 'Cluster Bomb' Based Bismuth Nano-in-Micro Spheres Formed Dry Powder Inhalation for Thermo-Radio Sensitization Effects of Lung Metastatic Breast Cancer. Adv Healthc Mater. 12:e22026222023.
91	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin. 61:250–281. 2011.
92	Kwiatkowski S, Knap B, Przystupski D, Saczko J, Kędzierska E, Knap-Czop K, Kotlińska J, Michel O, Kotowski K and Kulbacka J: Photodynamic therapy-mechanisms, photosensitizers and combinations. Biomed Pharmacother. 106:1098–1107. 2018.
93	Baumgartner R, Huber RM, Schulz H, Stepp H, Rick K, Gamarra F, Leberig A and Roth C: Inhalation of 5-aminolevulinic acid: A new technique for fluorescence detection of early stage lung cancer. J Photochem Photobiol B. 36:169–174. 1996.
94	Baghdan E, Duse L, Schüer JJ, Pinnapireddy SR, Pourasghar M, Schäfer J, Schneider M and Bakowsky U: Development of inhalable curcumin loaded Nano-in-Microparticles for bronchoscopic photodynamic therapy. Eur J Pharm Sci. 132:63–71. 2019.
95	Lehmann J, Agel MR, Engelhardt KH, Pinnapireddy SR, Agel S, Duse L, Preis E, Wojcik M and Bakowsky U: Improvement of pulmonary photodynamic therapy: Nebulisation of curcumin-loaded tetraether liposomes. Pharmaceutics. 13:12432021.
96	Zhang T, Bao J, Zhang M, Ge Y, Wei J, Li Y, Wang W, Li M and Jin Y: Chemo-photodynamic therapy by pulmonary delivery of gefitinib nanoparticles and 5-aminolevulinic acid for treatment of primary lung cancer of rats. Photodiagnosis Photodyn Ther. 31:1018072020.
97	Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG and Cascone T: Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 18:547–557. 2021.
98	Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y and Ellis PM: Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 18:259–273.e258. 2017.
99	De Ruysscher D, Faivre-Finn C, Nackaerts K, Jordan K, Arends J, Douillard JY, Ricardi U and Peters S: Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 31:41–49. 2020.
100	Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev. Cd0073092010.
101	Zarogoulidis P, Eleftheriadou E, Sapardanis I, Zarogoulidou V, Lithoxopoulou H, Kontakiotis T, Karamanos N, Zachariadis G, Mabroudi M, Zisimopoulos A and Zarogoulidis K: Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs. 30:1628–1640. 2012.
102	Lemarie E, Vecellio L, Hureaux J, Prunier C, Valat C, Grimbert D, Boidron-Celle M, Giraudeau B, le Pape A, Pichon E, et al: Aerosolized gemcitabine in patients with carcinoma of the lung: Feasibility and safety study. J Aerosol Med Pulm Drug Deliv. 24:261–270. 2011.
103	Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M and Kagamimori S: Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: Fundamental and clinical. Br J Cancer. 68:1146–1149. 1993.
104	Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, et al: Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 13:1246–1252. 2007.
105	Issa JP, Kantarjian HM and Kirkpatrick P: Azacitidine. Nat Rev Drug Discov. 4:275–276. 2005.
106	Cheng H, Zou Y, Shah CD, Fan N, Bhagat TD, Gucalp R, Kim M, Verma A, Piperdi B, Spivack SD, et al: First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer. Lung Cancer. 154:99–104. 2021.
107	Patra J K, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, et al: Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 16:712018.
108	Alavi M and Hamidi M: Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 34:2019.
109	Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A and Préat V: PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 161:505–522. 2012.
110	Kim I, Byeon HJ, Kim TH, Lee ES, Oh KT, Shin BS, Lee KC and Youn YS: Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials. 33:5574–5583. 2012.
111	Kim I, Byeon HJ, Kim TH, Lee ES, Oh KT, Shin BS, Lee KC and Youn YS: Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer. Biomaterials. 34:6444–6453. 2013.
112	Large DE, Abdelmessih RG, Fink EA and Auguste DT: Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 176:1138512021.
113	Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm. 4:807–818. 2007.
114	Zhang T, Chen Y, Ge Y, Hu Y, Li M and Jin Y: Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers. Acta Pharm Sin B. 8:440–448. 2018.
115	Knight V, Koshkina NV, Golunski E, Roberts LE and Gilbert BE: Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc. 115:395–404; discussion 404. 2004.
116	Shukla SK, Kulkarni NS, Farrales P, Kanabar DD, Parvathaneni V, Kunda NK, Muth A and Gupta V: Sorafenib loaded inhalable polymeric nanocarriers against non-small cell lung cancer. Pharm Res. 37:672020.
117	Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J and Omidi Y: Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev Ind Pharm. 43:1244–1253. 2017.
118	Sawant SS, Patil SM, Shukla SK, Kulkarni NS, Gupta V and Kunda NK: Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: Formulation development and in vitro evaluation. Drug Deliv Transl Res. 12:2474–2487. 2022.
119	Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B and Wang G: Ferroptosis: Past, present and future. Cell Death Dis. 11:882020.
120	Koppula P, Zhuang L and Gan B: Cystine transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
121	Mou Y, Wang J, Wu J, He D, Zhang C, Duan C and Li B: Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 12:342019.
122	Wang W, Wang W, Jin S, Fu F, Huang Z, Huang Y, Wu C and Pan X: Open pocket and tighten holes: Inhalable lung cancer-targeted nanocomposite for enhanced ferroptosis-apoptosis synergetic therapy. Chem Eng J. 458:1414872023.
123	Wang W, Fu F, Huang Z, Wang W, Chen M, Yue X, Fu J, Feng X, Huang Y, Wu C and Pan X: Inhalable biomimetic protein corona-mediated nanoreactor for self-amplified lung adenocarcinoma ferroptosis therapy. ACS Nano. 16:8370–8387. 2022.
124	Tan AC and Tan DSW: Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 40:611–625. 2022.
125	Min HY and Lee HY: Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharm Res. 44:146–164. 2021.
126	Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer. 22:402023.
127	Peters S, Reck M, Smit EF, Mok T and Hellmann MD: How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Ann Oncol. 30:884–896. 2019.
128	Sapalidis K, Zarogoulidis P, Pavlidis E, Laskou S, Katsaounis A, Koulouris C, Giannakidis D, Mantalovas S, Huang H, Bai C, et al: Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo study. A more efficient combination. J Cancer. 9:1973–1977. 2018.
129	Liu Y, Crowe WN, Wang L, Petty WJ, Habib AA and Zhao D: Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer. Nano Res. 16:5300–5310. 2023.
130	Kell SA, Kachura MA, Renn A, Traquina P, Coffman RL and Campbell JD: Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. Int Immunopharmacol. 66:296–308. 2019.
131	Fan Q, Li Z, Yin J, Xie M, Cui M, Fan C, Wang L and Chao J: Inhalable pH-responsive DNA tetrahedron nanoplatform for boosting anti-tumor immune responses against metastatic lung cancer. Biomaterials. 301:1222832023.
132	Dougan M, Luoma AM, Dougan SK and Wucherpfennig KW: Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 184:1575–1588. 2021.
133	Kara G, Calin GA and Ozpolat B: RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 182:1141132022.
134	Lamb YN: Inclisiran: First Approval. Drugs. 81:389–395. 2021.
135	Conde J, Ambrosone A, Hernandez Y, Tian F, McCully M, Berry CC, Baptista PV, Tortiglione C and de la Fuente JM: 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics. Nano Today. 10:421–450. 2015.
136	Merkel OM, Rubinstein I and Kissel T: siRNA delivery to the lung: what's new? Adv Drug Deliv Rev. 75:112–128. 2014.
137	Feldmann DP and Merkel OM: The advantages of pulmonary delivery of therapeutic siRNA. Ther Deliv. 6:407–409. 2015.
138	Taratula O, Garbuzenko OB, Chen AM and Minko T: Innovative strategy for treatment of lung cancer: Targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 19:900–914. 2011.
139	Zhao G, Ho W, Chu J, Xiong X, Hu B, Boakye-Yiadom KO, Xu X and Zhang XQ: Inhalable siRNA nanoparticles for enhanced tumor-targeting treatment of KRAS-Mutant non-small-cell lung cancer. ACS Appl Mater Interfaces. 15:31273–31284. 2023.
140	Luo CQ, Jang Y, Xing L, Cui PF, Qiao JB, Lee AY, Kim HJ, Cho MH and Jiang HL: Aerosol delivery of folate-decorated hyperbranched polyspermine complexes to suppress lung tumorigenesis via Akt signaling pathway. Int J Pharm. 513:591–601. 2016.
141	Gankhuyag N, Yu KN, Davaadamdin O, Lee S, Cho WY, Park C, Jiang HL, Singh B, Chae CH, Cho MH and Cho CS: Suppression of tobacco carcinogen-induced lung tumorigenesis by aerosol-delivered glycerol propoxylate triacrylate-spermine copolymer/short hairpin Rab25 RNA Complexes in Female A/J Mice. J Aerosol Med Pulm Drug Deliv. 30:81–90. 2017.
142	Fukushige K, Tagami T, Naito M, Goto E, Hirai S, Hatayama N, Yokota H, Yasui T, Baba Y and Ozeki T: Developing spray-freeze-dried particles containing a hyaluronic acid-coated liposome-protamine-DNA complex for pulmonary inhalation. Int J Pharm. 583:1193382020.
143	Garbuzenko OB, Kuzmov A, Taratula O, Pine SR and Minko T: Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 9:8362–8376. 2019.
144	Babu A, Templeton AK, Munshi A and Ramesh R: Nanoparticle-based drug delivery for therapy of lung cancer: Progress and challenges. J Nanomater. 2013.https://doi.org/10.1155/2013/863951.
145	Tharkar P, Madani AU, Lasham A, Shelling AN and Al-Kassas R: Nanoparticulate carriers: An emerging tool for breast cancer therapy. J Drug Target. 23:97–108. 2015.
146	Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R and Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2:751–760. 2007.
147	Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ and Postmus PE: Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 13:2414–2421. 2007.
148	Otterson GA, Villalona-Calero MA, Hicks W, Pan X, Ellerton JA, Gettinger SN and Murren JR: Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer. Clin Cancer Res. 16:2466–2473. 2010.
149	Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA and Knight V: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res. 10:2319–2326. 2004.
150	Rosière R, Berghmans T, De Vuyst P, Amighi K and Wauthoz N: the position of inhaled chemotherapy in the care of patients with lung tumors: Clinical feasibility and indications according to recent pharmaceutical progresses. Cancers (Basel). 11:3292019.
151	Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP and Zarogoulidis K: Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology. Int J Mol Sci. 13:10828–10862. 2012.
152	Durcan N, Murphy C and Cryan SA: Inhalable siRNA: Potential as a therapeutic agent in the lungs. Mol Pharm. 5:559–566. 2008.
153	Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, et al: A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 27:4566–4573. 2021.
154	Shevchenko IT and Resnik GE: Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma. 15:419–426. 1968.
155	Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ and Kris MG: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 26:639–643. 2008.
156	Forest V and Pourchez J: Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? Adv Drug Deliv Rev. 183:1141732022.
157	Luo MX, Hua S and Shang QY: Application of nanotechnology in drug delivery systems for respiratory diseases (Review). Mol Med Rep. 23:3252021.
158	Ali ME, McConville JT and Lamprecht A: Pulmonary delivery of anti-inflammatory agents. Expert Opin Drug Deliv. 12:929–945. 2015.
159	Mansour HM, Rhee YS and Wu X: Nanomedicine in pulmonary delivery. Int J Nanomedicine. 4:299–319. 2009.
160	Patton JS, Fishburn CS and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 1:338–344. 2004.
161	Yeagle P: Nanoparticles for drug delivery in lungs. Science. 356:37–38. 2017.
162	Zhong W, Zhang X, Zeng Y, Lin D and Wu J: Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 14:2067–2089. 2021.
163	Rau JL: The inhalation of drugs: Advantages and problems. Respir Care. 50:367–382. 2005.
164	Darwiche K, Zarogoulidis P, Karamanos NK, Domvri K, Chatzaki E, Constantinidis TC, Kakolyris S and Zarogoulidis K: Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: A future dilemma for micro-oncology. Future Oncol. 9:505–525. 2013.
165	Rosière R, Hureaux J, Levet V, Amighi K and Wauthoz N: Inhaled chemotherapy-Part 1: General concept and current technological challenges. Rev Mal Respir. 35:357–377. 2018.In French.
166	Hadrup N, Zhernovkov V, Jacobsen NR, Voss C, Strunz M, Ansari M, Schiller HB, Halappanavar S, Poulsen SS, Kholodenko B, et al: Acute phase response as a biological mechanism-of-action of (Nano)particle-Induced cardiovascular disease. Small. 16:e19074762020.
167	Ruge CA, Kirch J and Lehr CM: Pulmonary drug delivery: From generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med. 1:402–413. 2013.
168	Skibba M, Drelich A, Poellmann M, Hong S and Brasier AR: Nanoapproaches to modifying epigenetics of epithelial mesenchymal transition for treatment of pulmonary fibrosis. Front Pharmacol. 11:6076892020.
169	Osman NM, Sexton DW and Saleem IY: Toxicological assessment of nanoparticle interactions with the pulmonary system. Nanotoxicology. 14:21–58. 2020.
170	Wauthoz N, Rosière R and Amighi K: Inhaled cytotoxic chemotherapy: Clinical challenges, recent developments, and future prospects. Expert Opin Drug Deliv. 18:333–354. 2021.
171	Osman N, Kaneko K, Carini V and Saleem I: Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 15:821–834. 2018.
172	Pilcer G and Amighi K: Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 392:1–19. 2010.
173	Wauthoz N, Deleuze P, Hecq J, Roland I, Saussez S, Adanja I, Debeir O, Decaestecker C, Mathieu V, Kiss R and Amighi K: In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci. 39:402–411. 2010.
174	Fulzele SV, Chatterjee A, Shaik MS, Jackson T and Singh M: Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 23:2094–2106. 2006.
175	Shaik MS, Haynes A, McSween J, Ikediobi O, Kanikkannan N and Singh M: Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug. J Aerosol Med. 15:261–270. 2002.